# Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.

> **NCT00368186** · PHASE4 · TERMINATED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 51 (—)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** Pneumo 23

## Key facts

- **NCT ID:** NCT00368186
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-05
- **Primary completion:** —
- **Final completion:** 2002-11
- **Target enrollment:** 51 (—)
- **Last updated:** 2006-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00368186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00368186, "Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00368186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*